MARIA TEREZA ASSIS DE ALMEIDA

Índice h a partir de 2011
4
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina - Médico
Instituto da Criança, Hospital das Clínicas, Faculdade de Medicina - Médico

Filtros

Limpar filtros

Configurações

Resultados de Busca

Agora exibindo 1 - 10 de 17
  • conferenceObject
    National Studies for Childhood Germ Cell: 1073 Patients. Intermediate Risk with Cisplatin/Etoposide (PE) and no Bleomycin. High Risk Good Responders (HR-GR) with Excellent Results
    (2018) LOPES, L. F.; MACEDO, C. R. Donato; MARTINS, G. Eiras; BRANDALISE, S. R.; SONAGLIO, V.; SILVA, M. Milone; ALMEIDA, M. T. de Assis; WATUSI, F.; PIANOVSKI, M. Albonei; MELARAGNO, R.; SCRIDELLI, C. A.
  • article 2 Citação(ões) na Scopus
    Involvement of the central nervous system in neuroblastomas: A potential direct pathway
    (2020) ODONE-FILHO, Vicente; CRISTOFANI, Lilian Maria; MALUF, Paulo Taufi; ALMEIDA, Maria Tereza Assis; HALLEY, Nathalia; VINCE, Carolina Sgarioni Camargo; AZAMBUJA, Alessandra Milani Prandini de; BRUMATTI, Melina; LUBRAICO, Priscilla; LOPES, Luiz Heraldo Arouche da Camara; LEITE, Katia Ramos Moreira; SILVA, Joao Luis Fernandes; PLESE, Jose Pindaro Pereira; WELTMAN, Eduardo
    Although frequently disseminated to other anatomical sites, neuroblastoma (NB) is rarely reported as involving the central nervous system (CNS), which may reflect insufficient research in poorly controlled systemic disease. Here we demonstrate the involvement of the CNS in patients with NB over 18 months of age at diagnosis of extensive systemic disease. Meningeal metastases were observed even in the presence of complete systemic control. Although no improvement in patient's survival was observed, radiotherapy was effective in preventing CNS recurrence after observation of actual or previous dural disease. In conclusion, this study uncovered the uncommon pathologic involvement of the CNS in children with advanced NB and underscores the meningeal surface as a potential pathway for this to occur.
  • article 4 Citação(ões) na Scopus
    Orbital retinoblastoma: case report
    (2013) MABTUM, Eduardo Darahem; BONANOMI, Maria Teresa Brizzi Chizzotti; LIMA, Patricia Picciarelli de; ALMEIDA, Maria Tereza Assis de
    We describe the case of a 9-month old boy with unilateral retinoblastoma and bulftalmo. Primary enucleation was the treatment of choice due to the lack of visual prognosis. The histology of the enucleated eye showed massive choroidal invasion by the tumor and the optic nerve free of neoplastic tissue. Therefore, no adjuvant chemotherapy or radiotherapy was indicated. Three months after the enucleation, the patient returned with massive orbital retinoblastoma with exposure of the conjunctiva. Treated with chemotherapy, the patient has been in remission for 12 months. The risk factors for orbital recurrence are discussed.
  • conferenceObject
    FEASIBILITY OF THERAPEUTIC I131 METAIODOBENZYLGUANIDINE (MIBG) PREVIOUS TO BLOOD STEM CELL COLLECTION AS ""PURGING IN VIVO"" FOR HIGH-RISK NEUROBLASTOMAS (HRNB)
    (2014) ODONE-FILHO, V.; ALMEIDA, M. T. A.; BUCHPIGEL, C.; AZAMBUJA, A. M. P.; VINCE, C. S. C.; BRUMATTI, M.; NEVES, N. S. H.; BATISTA, G. L. F.; MALUF JR., P. T.; CRISTOFANI, L. M. C.
  • conferenceObject
    Biphenotypic Acute Leukemia: Results From a Group of Patients Treated at a Single Hospital
    (2020) KROHLING, D.; GUEDES, G.; CORREA, A.; SILVA, M.; GOMEZ, K.; NERO, L. Del; BREVIGLIERI, C.; ZAMPERLINI-NETTO, G.; ALMEIDA, M.; ODONE-FILHO, V.; CRISTOFANI, L.
  • conferenceObject
    Relapsed Acute Lymphoblastic Leukemia and Blinatumomab: Results From a Single Institution in Brazil Universidade de Sao Paulo
    (2020) ZAMPERLINI-NETTO, G.; FONSECA, M.; ALMEIDA, M.; ODONE-FILHO, V.; TEIXEIRA, R.; FERNANDES, J.; AZAMBUJA, A.; DUTRA, A.; BREVIGLIERI, C.; CRISTOFANI, L.
  • conferenceObject
    LONG TERM COMPLICATIONS IN CHILDREN TREATED FOR ADVANCED NEUROBLASTOMA
    (2012) HALLEY, Nathalia; CRISTOFANI, Lilian Maria; ALMEIDA, Maria Teresa Assis; MALUF-JUNIOR, Paulo Taufi; CORNACCHIONI, Ana Lucia Beltrati; TEIXEIRA, Roberto Augusto Plaza; ZAMPERLINI-NETO, Gabriele; GOMES, Alessandra Araujo; ODONE-FILHO, Vicente
    Purpose: Advanced neuroblastoma (stage 3 and 4) requires aggressive treatment, including surgery, chemo and radiotherapy and autologous bone marrow transplantation. Although long term survival rates are disappointing, those children who survive are prone to develop long term complications. Our aim is to report the long term complications rate and quality in children treated for stage 3 and 4 neuroblastoma. Methods: The charts of stage 3 and 4 children with neuroblastoma treated from January/1983 through October/2003 were reviewed and those surviving and with no evidence of disease for more than 5 years were selected. Late effects were classified as second malignancies, endocrinological, neuromotor, hepatic, sensorial, benign tumors, infectious diseases and psychiatric disease and others. Associations with treatment modalities were disclosed. Results: Among 263 children with stage 3 and 4 neuroblastoma, 40 (15%) are long term survivors. 20/40 (50%) present one or more complications, being 2 (10%) second malignant neoplasia, 4 (20%) endocrinological disturbances, 4 (20%) neuromotor, 5 (25%) hepatic, 4 (20%) sensorial, 3 (1.1%) benign tumors, and infertility, psychiatric disease and hepatitis C infection in 1 (5%) episode each. 10/20 (50%) of the children were less than 18 months at diagnosis, and 12/20 (60%) were stage 3 and 8/20 (40%) were stage 4. All children were submitted to chemotherapy and 7/20 (35%) to autologous bone marrow transplantation. In 10/20 (50%) patients radiotherapy was also included, and 4/10 (40%) presented functional lesions in the irradiated field. All endocrinologic sequelae were detected in the ABMT group. Second malignant neoplasia were not related to RDT(1 ALL and 1 thyroid carcinoma). Conclusion: Children surviving aggressive therapy for neuroblastoma are at risk of late effects, particularly endocrinological and neurological complications, requiring close observation to prompt intervention when necessary, avoiding impairments in quality of life or even life threatening situations. Second malignant neoplasia require special concern.
  • article 0 Citação(ões) na Scopus
    Acute promyelocytic leukemia in childhood and adolescence: treatment results of a modified AIDA protocol at a Brazilian center
    (2023) BREVIGLIERI, Carla Nolasco Monteiro; ALMEIDA, Maria Tereza Assis de; NETO, Gabriele Zampelini; TEIXEIRA, Roberto Augusto Plaza; ODONE-FILHO, Vicente; CRISTOFANI, Lilian Maria
    Introduction: Acute promyelocytic leukemia currently presents an excellent chance of cure with protocols based on all-trans-retinoic acid (ATRA) and anthracycline or only differentiation agents. However, high early mortality rates continue to be reported Methods: Between 2000 and 2018, patients were enrolled and retrospectively analyzed by medical records. A modified AIDA protocol, with a 1-year shortening of the treatment duration, reduction in the number of drugs and a strategy to reduce early mortality by the postponement of the initiation of anthracyclines were employed. Overall and event-free survival rates and toxicity were analyzed Results: Thirty-two patients were enrolled, of whom 56% were female, with a median age of 12 years and 34% belonged to the high-risk group. Two patients had the hypogranular variant and three had another cytogenetic alteration, in addition to the t(15;17). The median start of the first anthracycline dose was 7 days. There were two early deaths (6%) due to central nervous system (CNS) bleeding. All patients achieved molecular remission after the consolidation phase. Two children relapsed and were rescued by arsenic trioxide and hematopoietic stem cell transplantation. The presence of disseminated intravascular coagulation (DIC) at diagnosis (p = 0.03) was the only factor with survival impact. The five-year event-free survival (EFS) was 84% and 5-year overall survival (OS) was 90% Conclusion: The survival results were comparable to those found in the AIDA protocol, with a low rate of early mortality in relation to the Brazilian reality. (C) 2022 Published by Elsevier Espana, S.L.U. on behalf of Associacao Brasileira de Hematologia, Hemoterapia e Terapia Celular. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
  • article 42 Citação(ões) na Scopus
    Results of a Randomized, Prospective Clinical Trial Evaluating Metronomic Chemotherapy in Nonmetastatic Patients With High-Grade, Operable Osteosarcomas of the Extremities: A Report From the Latin American Group of Osteosarcoma Treatment
    (2017) SENERCHIA, Andreza A.; MACEDO, Carla Renata; FERMAN, Sima; SCOPINARO, Marcelo; CACCIAVILLANO, Walter; BOLDRINI, Erica; MORAES, Vera Lucia Lins de; REY, Guadalupe; OLIVEIRA, Claudia T. de; CASTILLO, Luis; ALMEIDA, Maria Tereza; BORSATO, Maria Luisa; LIMA, Eduardo; LUSTOSA, Daniel; BARRETO, Jose Henrique; EL-JAICK, Tatiana; AGUIAR, Simone; BRUNETTO, Algemir; GREGGIANI, Lauro; COGO-MOREIRA, Hugo; ATALLAH, Alvaro; PETRILLI, Antonio Sergio
    BACKGROUND: Metronomic chemotherapy (MC) consists of the administration of a low dose of chemotherapy on a daily or weekly basis without a long break to achieve an antitumoral effect through an antiangiogenic effect or stimulation of the immune system. The potential effect of MC with continuous oral cyclophosphamide and methotrexate in patients with high-grade operable osteosarcomas (OSTs) of the extremities was investigated. METHODS: Patients with high-grade OSTs who were 30 years old or younger were eligible for registration at diagnosis. Eligibility for randomization included 1) nonmetastatic disease and 2) complete resection of the primary tumor. The study design included a backbone of 10 weeks of preoperative therapy with methotrexate, adriamycin, and platinum (MAP). After surgery, patients were randomized between 2 arms to complete 31 weeks of MAP or receive 73 weeks of MC after MAP. The primary endpoint was event-free survival (EFS) from randomization. RESULTS: There were 422 nonmetastatic patients registered (May 2006 to July 2013) from 27 sites in 3 countries (Brazil, Argentina and Uruguay), and 296 were randomized to MAP plus MC (n = 139) or MAP alone (n = 157). At 5 years, the EFS cumulative proportions surviving in the MAP-MC group and the MAP-alone group were 61% (standard error [SE], 0.5%) and 64% (SE, 0.5%), respectively, and they were not statistically different (Wilcoxon [Gehan] statistic = 0.724; P = .395). The multivariate analysis showed that necrosis grades 1 and 2, tumor size, and amputation were associated with shorter EFS. CONCLUSIONS: According to the current follow-up, EFS with MAP plus MC is not statistically superior to EFS with MAP alone in patients with high-grade, resectable OSTs of the extremities. (C) 2016 American Cancer Society.
  • conferenceObject
    Multicentric Study of Interval-Compressed Multiagent and Randomized Metronomic Chemotherapy for Patients with Localized Ewing Sarcoma: Results of the Latin American Pediatric Oncology Group Trial
    (2019) GREGIANIN, L.; ROSE, A.; VILLARROEL, M.; FERMAN, S.; ALMEIDA, M. T.; DUFORT, G.; SALGADO, C.; CEA, G.; LASTRA, A.; AMARAL, A. B. Costa Neves Do; EPELMAN, S.; SELISTRE, S. de Almeida; RODRIGUES, K. E. de Sa; SANTOS, J. F. Cerutti; PINTO, L. Guimaraes; BRUNETTO, A. Lunardi